Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 23, 2022CirculationOpen Access

Dapagliflozin increased ketone-related and short-chain acylcarnitine as well as medium-chain acylcarnitine metabolite clusters compared with placebo (nominal P=0.01, false discovery rate-adjusted P=0.08 for both clusters).

View Full Paper
Ask AI
Bookmark
Share

Why the study?

SGLT2 inhibitors are foundational therapy in HFrEF, but the underlying mechanisms of benefit are not well defined.

Does dapagliflozin alter metabolic pathways compared to placebo in patients with HFrEF?

Population

234 HFrEF patients with targeted metabolomic data

Comparison

Dapagliflozin vs placebo

Design

Placebo-controlled trial

Follow-up

12 weeks

Authors

SSSenthil SelvarajZFZhuxuan FuPJPhilip G. Jones

Discussion

Loading...

Member takes

Overview

Dapagliflozin-associated metabolomic shifts in HFrEF warrant mechanistic follow-up; leaves open whether ketone or acylcarnitine changes mediate outcomes.

Structured PICO

Does dapagliflozin alter metabolic pathways compared to placebo in patients with HFrEF?

P
Population
234 participants with heart failure with reduced ejection fraction (HFrEF), mean age 62.0±11.1 years, 25% women, 38% Black, mean ejection fraction 27±8%.
I
Intervention
Dapagliflozin
C
Comparator
Placebo
O
Outcome
Changes in principal components analysis-defined metabolite clusters (63 metabolites) at 12 weekssurrogate

Dapagliflozin alters key metabolic pathways in HFrEF, supporting a role for altered ketone and fatty acid biology as a potential mechanism of benefit.

Cite This Study

Selvaraj et al. (2022) studied this question.

synapsesocial.com/papers/6a7d17072935e92dbc775576https://doi.org/10.1161/circulationaha.122.060402
View Full Paper
Ask AI
Bookmark
Share